However, definitive evidence addressing the extent to which the lessons from GEMMs of Brca2‐deficient pancreatic cancers can be applied to human neoplasia awaits the results of more extensive genome sequencing studies on pancreatic cancer samples from patients harbouring germline BRCA2 mutations. This evidence concerns the gene BRCA2 and pancreatic neoplasm.